SB

Sebastiaan la Bastide

Head Of Strategy & Lifecycle Services at Ventana Medical Systems

Sebastiaan la Bastide has a diverse work experience spanning several companies and industries. Starting in 1994, they worked as a Graduate researcher at Philips Research Laboratories, where they focused on designing and implementing learning control algorithms for a wafer stepper. In 1995, Sebastiaan worked as a Project Manager at both Origin and ASML, where they served as a Project Manager/Product Manager.

Sebastiaan then joined Siemens as a Summer Associate in 2001 before moving to Roche in 2002. At Roche, they held several roles, including Manager Strategic Planning, Head of Program Management, Head of New Concept Incubator, and Director of Innovation, Diabetes Management Solutions.

In 2015, Sebastiaan joined Ventana Medical Systems, where they initially held the position of Director Strategic Planning before being promoted to Head of Strategy & Lifecycle Services in 2017.

Sebastiaan la Bastide completed their Master of Science degree in Mechanical Engineering from Delft University of Technology in 1995. Sebastiaan then pursued a Master of Business Administration (MBA) in General Management and Entrepreneurship from IESE Business School, which they completed between 2000 and 2002.

Location

Tucson, United States

Links

Previous companies


Org chart


Teams

This person is not in any teams


Offices


Ventana Medical Systems

Ventana Medical Systems, Inc., a member of the Roche Group, innovates and manufactures instruments and reagents that automate tissue processing and slide staining for cancer diagnostics. VENTANA solutions are used in clinical histology and drug development research laboratories worldwide. The company’s intuitive, integrated staining and workflow management platforms that optimize laboratory efficiencies to reduce errors – support diagnosis and inform treatment decisions for anatomic pathology professionals. Together with Roche, Ventana is driving personalized healthcare through accelerated drug discovery and the development of “companion diagnostics” to identify the patients most likely to respond favorably to specific therapies. Visit www.ventana.com to learn more.


Employees

10,000+

Links